1. B cells in head and neck squamous cell carcinoma: current opinion and novel therapy.
- Author
-
Guo, Xinyue, Xu, Licheng, Nie, Luan, Zhang, Chenyu, Liu, Yaohui, Zhao, Rui, Cao, Jing, Tian, Linli, and Liu, Ming
- Subjects
- *
B cells , *SQUAMOUS cell carcinoma , *IMMUNE checkpoint inhibitors , *T cells , *TUMOR microenvironment , *RADIOTHERAPY - Abstract
Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumour. Despite advancements in surgery, radiotherapy and chemotherapy, which have improved the prognosis of most patients, a subset of patients with poor prognoses still exist due to loss of surgical opportunities, postoperative recurrence, and metastasis, among other reasons. The tumour microenvironment (TME) is a complex organization composed of tumour, stromal, and endothelial cells. Communication and interaction between tumours and immune cells within the TME are increasingly being recognized as pivotal in inhibiting or promoting tumour development. Previous studies on T cells in the TME of HNSCC have yielded novel therapeutic possibilities. However, the function of B cells, another adaptive immune cell type, in the TME of HNSCC patients has yet to be determined. Recent studies have revealed various distinct subtypes of B cells and tertiary lymphoid structures (TLSs) in the TME of HNSCC patients, which are believed to impact the efficacy of immune checkpoint inhibitors (ICIs). Therefore, this paper focuses on B cells in the TME to explore potential directions for future immunotherapy for HNSCC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF